Skip to main content

Table 4 Scoring based on the primary malignancy

From: Analysis of the predictive role and new proposal for surgical strategies based on the modified Tomita and Tokuhashi scoring systems for spinal metastasis

Primary malignancy No. Survival period (months) Tokuhashi score Tomita score Prognosis
   Mean (95% CI) Median (95% CI) Original Adjusted Original Adjusted  
Lymphoma 3 53.9 (20.1 - 87.8) - - 5 - 1 Favor
MM* 5 46.5 (33.8 - 59.2) - - 5 - 1
Thyroid 2 45.9 (5.9 - 85.9) 17.1 5 5 1 1
Breast 5 31.4 (15.4 - 47.4) - 5 5 1 1
Uterus 4 14.4 (0.0 - 29.5) 3.9 (0.0 - 12.9) 3 4 2 2 Intermediate
Liver 19 12.2 (6.6 - 17.7) 8.5 (5.6 - 11.5) 1 4 4 2
Prostate 6 10.9 (1.6 - 20.2) 5.1 (4.1 - 6.0) 5 3 1 2
Kidney 7 10.8 (5.9 - 15.7) 9.2 (5.2 - 13.3) 3 3 2 2
Lung 23 6.0 (3.7 - 8.3) 4.3 (1.3 - 7.3) 0 1 4 4 Poor
Esophagus 3 6.0 (0.0 - 13.4) 2.3 (2.0 - 2.6) 0 1 - 4
Colon 5 6.0 (3.8 - 8.2) 4.7 (4.5 - 4.9) 2 1 4 4
Stomach 4 5.5 (2.0 - 8.9) 3.4 (0.8 - 5.9) 0 0 - 4
GB/Biliary 3 3.5 (0.7 - 6.3) 4.5 (0.0 - 10.7) 1 0 - 4
Rectum 9 3.1 (2.1 - 4.0) 3.3 (2.4 - 4.3) 4 0 - 4
Bladder 1 2.7 2.7 0 0 - 4
Others* 13 18.9 (7.3 - 30.4) 6.3 (0.0 - 14.3) 2 2 - 2 Intermediate
Overall 112 17.3 (12.6 - 22.1) 5.8 (5.0 - 6.7)      
  1. Primary malignancy was categorized according to the Tokuhashi score (0 to 5) or Tomita score (1, 2, or 4). The scores for certain primary malignancies, including uterine, liver, and prostate cancers, were reassigned for adjustment. The scores for colon and rectal cancers in the Tokuhashi system were reassigned to indicate a worse prognosis in line with the Tomita system. *Other types of primary malignancy: head and neck region, mediastinum, and other malignancies, that is, pancreatic cancer, urethral cancer, adrenal cancer, and melanoma. MM, multiple myeloma; GB, gall bladder; MPNST, malignant peripheral nerve sheath tumor. Dash means no value for parameter.